Literature DB >> 15256870

Charitable State-Controlled Foundation Human Tissue and Cell Research: Ethic and Legal Aspects in the Supply of Surgically Removed Human Tissue For Research in the Academic and Commercial Sector in Germany.

Wolfgang E. Thasler1, Thomas S. Weiss, Kerrin Schillhorn, Peter-Tobias Stoll, Bernhard Irrgang, Karl-Walter Jauch.   

Abstract

Tissue engineering using human cells and tissue has one of the greatest scientific and economical potential in the coming years. There are public concerns during the ongoing discussion about future trends in life sciences and if ethic boundaries might be respected sufficiently in the course of striving for industrial profit and scientific knowledge. Until now, the legal situation of using human tissue material for research is not clear. Accordingly, transparency of action and patients' information are a central component when handling patient material inside and outside of the patient-specific treatment. Whereas in the field of therapeutic use of tissue (e.g. transplantation) there is an emergency situation by the shortage of organs with the risk of the premature death of the potential recipient, this cannot be claimed for tissue donation for research. The basis of every surgical operation is the treatment contract, which places the doctor under obligation to the careful exercise of medical treatment containing the patient's informed consent. This contract only covers the treatment that is intended to cure the patient and the medical measures that are necessary therefor. The further scientific use of body-substances, which are discarded after an operation, are not included. Therefore a personal and independent written enlightenment of the patient and a declaration of informed consent is necessary. Examples of guidelines for tissue supply, Patients information and consent were worked out by theologists, lawyers, scientists and physicians reflecting their practical experience in transplant surgery and liver cell research. As a consequence to cover the ethical and legal aspect of tissue donation in Germany a charitable state-controlled foundation Human Tissue and Cell Research (HTCR) was introduced and established.

Entities:  

Year:  2003        PMID: 15256870     DOI: 10.1023/A:1026392429112

Source DB:  PubMed          Journal:  Cell Tissue Bank        ISSN: 1389-9333            Impact factor:   1.522


  53 in total

1.  RNA stability in human liver: comparison of different processing times, temperatures and methods.

Authors:  Serene M L Lee; Celine Schelcher; Sevdije Gashi; Stefanie Schreiber; Reinhard M K Thasler; Karl-Walter Jauch; Wolfgang E Thasler
Journal:  Mol Biotechnol       Date:  2013-01       Impact factor: 2.695

2.  Isolation of human hepatocytes by a two-step collagenase perfusion procedure.

Authors:  Serene M L Lee; Celine Schelcher; Maresa Demmel; Maria Hauner; Wolfgang E Thasler
Journal:  J Vis Exp       Date:  2013-09-03       Impact factor: 1.355

3.  STAT3 inhibition reduces toxicity of oncolytic VSV and provides a potentially synergistic combination therapy for hepatocellular carcinoma.

Authors:  S Marozin; J Altomonte; K A Muñoz-Álvarez; A Rizzani; E N De Toni; W E Thasler; R M Schmid; O Ebert
Journal:  Cancer Gene Ther       Date:  2015-05-01       Impact factor: 5.987

Review 4.  [Challenges in the organization of investigator initiated trials: in transplantation medicine].

Authors:  A A Schnitzbauer; P E Lamby; I Mutzbauer; J von Hassel; E K Geissler; H J Schlitt
Journal:  Chirurg       Date:  2011-03       Impact factor: 0.955

5.  Cell therapeutic options in liver diseases: cell types, medical devices and regulatory issues.

Authors:  Andreas K Nussler; Katrin Zeilinger; Lilianna Schyschka; Sabrina Ehnert; Jörg C Gerlach; Xueying Yan; Serene M L Lee; Maren Ilowski; Wolfgang E Thasler; Thomas S Weiss
Journal:  J Mater Sci Mater Med       Date:  2011-04-03       Impact factor: 3.896

6.  A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular Carcinoma.

Authors:  Sarah Abdullahi; Melanie Jäkel; Sabine J Behrend; Katja Steiger; Geoffrey Topping; Teresa Krabbe; Alessio Colombo; Volker Sandig; Tobias S Schiergens; Wolfgang E Thasler; Jens Werner; Stefan F Lichtenthaler; Roland M Schmid; Oliver Ebert; Jennifer Altomonte
Journal:  J Virol       Date:  2018-11-12       Impact factor: 5.103

7.  Towards a richer debate on tissue engineering: a consideration on the basis of NEST-ethics.

Authors:  A J M Oerlemans; M E C van Hoek; E van Leeuwen; S van der Burg; W J M Dekkers
Journal:  Sci Eng Ethics       Date:  2012-11-15       Impact factor: 3.525

8.  Under the pretence of autonomy: contradictions in the guidelines for human tissue donation.

Authors:  Michael Steinmann
Journal:  Med Health Care Philos       Date:  2009-02-14

9.  Cell cycle progression or translation control is not essential for vesicular stomatitis virus oncolysis of hepatocellular carcinoma.

Authors:  Sabrina Marozin; Enrico N De Toni; Antonia Rizzani; Jennifer Altomonte; Alexandra Junger; Günter Schneider; Wolfgang E Thasler; Nobuyuki Kato; Roland M Schmid; Oliver Ebert
Journal:  PLoS One       Date:  2010-06-07       Impact factor: 3.240

10.  Genetic inactivation of the Fanconi anemia gene FANCC identified in the hepatocellular carcinoma cell line HuH-7 confers sensitivity towards DNA-interstrand crosslinking agents.

Authors:  Andreas Palagyi; Kornelia Neveling; Ursula Plinninger; Andreas Ziesch; Bianca-Sabrina Targosz; Gerald U Denk; Stephanie Ochs; Antonia Rizzani; Daniel Meier; Wolfgang E Thasler; Helmut Hanenberg; Enrico N De Toni; Florian Bassermann; Claus Schäfer; Burkhard Göke; Detlev Schindler; Eike Gallmeier
Journal:  Mol Cancer       Date:  2010-05-28       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.